Indication
T-cell neoplasm
1 clinical trial
1 drug
Clinical trial
Phase 2, Open Label, Multicenter Study of Pacritinib in Relapsed/Refractory T-cell Lymphoproliferative NeoplasmsStatus: Recruiting, Estimated PCD: 2027-11-01
Drug
Pacritinib1 clinical trial
1 drug